NCT02120794已完成不适用
Multi-Center, Prospective, Observational Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System in Pediatric Patients With Type 1 Diabetes
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 194
- 试验地点
- 32
- 主要终点
- Overall Mean Change in A1C
研究概览
简要总结
The study objective is to demonstrate that home use of Threshold Suspend (TS) is not associated with glycemic deterioration in pediatric patients with type 1 diabetes, as measured by change in A1C.
详细描述
This study is a longitudinal, multi-center trial that aims to observe the Threshold Suspend (TS) feature with a sensor-augmented insulin pump in patients 7-15 years with Type 1 diabetes. The study will measure the change in A1C from baseline over a period of one year while subjects are wearing the study pump.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 15 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is age 2 to 15 at time of screening
- •Subject has been diagnosed with type 1 diabetes mellitus and must have been diagnosed for at least one year prior to screening
- •Subject is currently transitioning from pump therapy, with or without continued glucose monitoring (CGM), to the 530G insulin pump system.
- •Subject is willing to perform greater than or equal to 4 finger stick blood glucose measurements daily
- •Subject is willing to perform required sensor calibrations
- •Subject is willing to wear the system (Pump, glucose sensors, meter) continuously throughout the study
- •Subject is willing to upload data every 21 days from the study pump
- •Subject must have Internet access and access to a computer system that meets the requirements for uploading the pumps. This may include use of family or friend's computer system with Internet access.
- •Subject is using either Humalog or Novolog at time of Screening and plans to use either of those insulins throughout the study
排除标准
- •Subject is actively participating in an investigational study (drug or device) wherein he/she is receiving treatment from an investigational study drug or investigational study device.
- •Women of child-bearing potential who have a positive pregnancy test at screening or plan to become pregnant during the course of the study
- •Subject is being treated for hyperthyroidism at time of screening
- •Subject has an abnormality (>1.8mg/dL) in creatinine at time of screening visit
- •Subject has an abnormality (out of reference range) in thyroid-stimulating hormone (TSH) at time of screening visit; If TSH is out of range, Free T3 and Free T4 will be tested; subject may be included with TSH out of range as long as Free T3 and Free T4 are in normal reference range.
- •Subject has taken any oral, injectable, or IV steroids within 8 weeks from time of screening visit, or plans to take any oral, injectable, or IV steroids during the course of the study
- •Subject is currently abusing illicit drugs
- •Subject is currently abusing prescription drugs
- •Subject is currently abusing alcohol
- •Subject is using pramlintide (Symlin) at time of screening
- •Subject has a sickle cell disease, hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening
- •Subject plans to receive red blood cell transfusion or erythropoietin over the course of study participation
- •Subject diagnosed with current eating disorder such as anorexia or bulimia
- •Subject has been diagnosed with chronic kidney disease that results in chronic anemia
- •Subject is on dialysis
- •Subject is already on a 530G system with CGM for 8 days or more.
研究组 & 干预措施
530G insulin pump
Experimental
Subjects will use 530G insulin pump with Threshold Suspend (TS) feature for one year.
干预措施: 530G Insulin pump (Device)
结局指标
主要结局
Overall Mean Change in A1C
时间窗: Baseline and 1 year after screening
The overall mean change in A1C from baseline to 1 year will be estimated and compared by a non-inferiority test with an A1C margin of 0.4% and a significance level of 0.025 (one-sided). Among the 136 subjects who completed the study, 132 had both baseline and end of study A1c. Therefore, primary endpoint was based on 132 subjects.
次要结局
- Mean Change in A1C From Baseline to 1 Year, Stratified by Different A1c Subgroups(Baseline and 1 year after screening)
研究者
研究点 (32)
Loading locations...
相似试验
招募中
不适用
Long-term Home-based Exercise for Patients With COPD: the COPDtoParis ProjectTelerehabilitationCOPDQuality of LifeMobility LimitationNCT06235502Aalborg University Hospital40
已完成
3 期
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)Pancreatic NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsPancreatic DiseasesDigestive System DiseasesEndocrine System DiseasesGemcitabineAntimetabolites, AntineoplasticNCT01964430Celgene866
已完成
不适用
Study to Evaluate Changes in Smokers Using on!® Nicotine PouchesTobacco UseNCT05664672Altria Client Services LLC149
已完成
不适用
Joint Health StudyHemophilia BNCT03358836Bloodworks8
已完成
不适用
Observational Study to Determine the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Locally Advanced Basal Cell Carcinoma (laBCC)Carcinoma, Basal CellNCT02674009Hoffmann-La Roche67